{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:12:54Z","timestamp":1790817174431,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100010793","name":"Pfizer Japan Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010793","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s12325-024-03070-x","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T16:58:34Z","timestamp":1735059514000},"page":"1094-1107","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical Features and Current Pharmacotherapy of OAB in Practice: Ideal and Reality"],"prefix":"10.1007","volume":"42","author":[{"given":"Kazuna","family":"Tsubouchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisatomi","family":"Arima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiki","family":"Emoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Mikami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikao","family":"Aoyagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Matsuzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Tominaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naotaka","family":"Gunge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Okabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chizuru","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiro","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3618-5214","authenticated-orcid":false,"given":"Nobuhiro","family":"Haga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,24]]},"reference":[{"key":"3070_CR1","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1111\/iju.13401","volume":"24","author":"Y Homma","year":"2017","unstructured":"Homma Y, Gotoh M, Kawauchi A, et al. Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia. Int J Urol. 2017;24:716\u201329.","journal-title":"Int J Urol"},{"key":"3070_CR2","doi-asserted-by":"crossref","unstructured":"Takahashi S, Takei M, Asakura H, et al. Clinical guidelines for female lower urinary tract symptoms (second edition). Int J Urol. 2021;28:474\u201392.","DOI":"10.1111\/iju.14492"},{"key":"3070_CR3","unstructured":"AUA. AUA\/SUFU Guideline. https:\/\/www.auanet.org\/guidelines-and-quality\/guidelines\/overactive-bladder-(oab)-guideline. Accessed Sep 30, 2024."},{"key":"3070_CR4","doi-asserted-by":"publisher","first-page":"175628722110390","DOI":"10.1177\/17562872211039034","volume":"13","author":"C Fontaine","year":"2021","unstructured":"Fontaine C, Papworth E, Pascoe J, Hashim H. Update on the management of overactive bladder. Ther Adv Urol. 2021;13:17562872211039034.","journal-title":"Ther Adv Urol"},{"key":"3070_CR5","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s40266-019-00694-5","volume":"36","author":"BT Suehs","year":"2019","unstructured":"Suehs BT, Caplan EO, Hayden J, Ng DB, Gaddy RR. The relationship between anticholinergic exposure and falls, fractures, and mortality in patients with overactive bladder. Drugs Aging. 2019;36:957\u201367.","journal-title":"Drugs Aging"},{"key":"3070_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-026391","volume":"9","author":"SM Szabo","year":"2019","unstructured":"Szabo SM, Gooch K, Schermer C, et al. Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study. BMJ Open. 2019;9:e026391.","journal-title":"BMJ Open"},{"key":"3070_CR7","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1111\/iju.13758","volume":"25","author":"M Yoshida","year":"2018","unstructured":"Yoshida M, Kato D, Nishimura T, Van Schyndle J, Uno S, Kimura T. Anticholinergic burden in the Japanese elderly population: use of antimuscarinic medications for overactive bladder patients. Int J Urol. 2018;25:855\u201362.","journal-title":"Int J Urol"},{"key":"3070_CR8","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1111\/jgs.13702","volume":"63","author":"By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel","year":"2015","unstructured":"By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63:2227\u201346.","journal-title":"J Am Geriatr Soc"},{"key":"3070_CR9","doi-asserted-by":"publisher","first-page":"231","DOI":"10.5213\/inj.2040082.041","volume":"24","author":"YJ Kim","year":"2020","unstructured":"Kim YJ, Tae BS, Bae JH. Cognitive function and urologic medications for lower urinary tract symptoms. Int Neurourol J. 2020;24:231\u201340.","journal-title":"Int Neurourol J"},{"key":"3070_CR10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/luts.12262","volume":"11","author":"LC Chen","year":"2019","unstructured":"Chen LC, Kuo HC. Pathophysiology of refractory overactive bladder. Low Urin Tract Symptoms. 2019;11:177\u201381.","journal-title":"Low Urin Tract Symptoms"},{"key":"3070_CR11","first-page":"S580","volume":"6","author":"P Abrams","year":"2000","unstructured":"Abrams P, Kelleher C, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am J Manag Care. 2000;6:S580\u201390.","journal-title":"Am J Manag Care"},{"key":"3070_CR12","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1097\/JU.0000000000003209","volume":"209","author":"K Tsubouchi","year":"2023","unstructured":"Tsubouchi K, Arima H, Abe M, et al. Effect of pharmacotherapy for overactive bladder on the incidence of and factors related to urinary tract infection: a systematic review and meta-analysis. J Urol. 2023;209:665\u201374.","journal-title":"J Urol"},{"key":"3070_CR13","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/nau.24827","volume":"41","author":"B Welk","year":"2022","unstructured":"Welk B, Etaby K, McArthur E, Chou Q. The risk of delirium and falls or fractures with the use of overactive bladder anticholinergic medications. Neurourol Urodyn. 2022;41:348\u201356.","journal-title":"Neurourol Urodyn"},{"key":"3070_CR14","unstructured":"JMDC. JMDC Claims Database. https:\/\/www.jmdc.co.jp\/en\/jmdc-claims-database\/ Accessed Sep 30, 2024."},{"key":"3070_CR15","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/iju.15117","volume":"30","author":"M Suzuki","year":"2023","unstructured":"Suzuki M, Yamamoto M, Shiratori T, Naito A, Nakamura M. Evaluation of trends in prescription drugs for overactive bladder in Japanese patients. Int J Urol. 2023;30:331\u20133.","journal-title":"Int J Urol"},{"key":"3070_CR16","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1111\/iju.15454","volume":"31","author":"T Mitsui","year":"2024","unstructured":"Mitsui T, Sekido N, Masumori N, et al. Prevalence and impact on daily life of lower urinary tract symptoms in Japan: results of the 2023 Japan Community Health Survey (JaCS 2023). Int J Urol. 2024;31:747\u201354.","journal-title":"Int J Urol"},{"key":"3070_CR17","doi-asserted-by":"publisher","first-page":"9337","DOI":"10.1038\/s41598-020-65989-9","volume":"10","author":"N Cebron Lipovec","year":"2020","unstructured":"Cebron Lipovec N, Jazbar J, Kos M. Anticholinergic burden in children, adults and older adults in Slovenia: a nationwide database study. Sci Rep. 2020;10:9337.","journal-title":"Sci Rep"},{"key":"3070_CR18","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s40266-020-00792-9","volume":"37","author":"G Lozano-Ortega","year":"2020","unstructured":"Lozano-Ortega G, Walker DR, Johnston K, et al. Comparative safety and efficacy of treatments for overactive bladder among older adults: a network meta-analysis. Drugs Aging. 2020;37:801\u201316.","journal-title":"Drugs Aging"},{"key":"3070_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/nau.25541","author":"K Tsubouchi","year":"2024","unstructured":"Tsubouchi K, Maeda T, Emoto T, et al. Improvement of medication adherence for desmopressin by adjusting the prescription dosage in male patients with overactive bladder: a claims database analysis. Neurourol Urodyn. 2024. https:\/\/doi.org\/10.1002\/nau.25541. (Online ahead of print).","journal-title":"Neurourol Urodyn"},{"key":"3070_CR20","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.3390\/jcm11144087","volume":"11","author":"N Izumi","year":"2022","unstructured":"Izumi N, Matsuo T, Matsukawa Y. Associations among physician\u2013patient communication, patient satisfaction, and clinical effectiveness of overactive bladder medication: a survey of patients with overactive bladder. J Clin Med. 2022;11:4087.","journal-title":"J Clin Med"},{"key":"3070_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.803970","volume":"12","author":"KM Liao","year":"2022","unstructured":"Liao KM, Lio KL, Chou YJ, Kuo CC, Chen CY. The association between urinary tract infection and overactive bladder treatment. Front Pharmacol. 2022;12:803970.","journal-title":"Front Pharmacol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03070-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-03070-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03070-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T10:53:15Z","timestamp":1738407195000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-03070-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,24]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["3070"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-03070-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,24]]},"assertion":[{"value":"4 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hiroshi Nakazawa, Takahiro Kitano, and Masashi Mikami were involved in research and preparation of the manuscript as employees of Pfizer Japan Inc. Kazuna Tsubouchi, Hisatomi Arima, Taiki Emoto, Chikao Aoyagi, Hiroshi Matsuzaki, Kosuke Tominaga, Naotaka Gunge, Takeshi Miyazaki, Yu Okabe, Nobuyuki Nakamura, Yuichiro Fukuhara, Masahiro Tachibana, Chizuru Nakagawa, Fumihiro Yamazaki, and Nobuhiro Haga did not receive any compensation related to this study from Pfizer Japan Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"As we used the already anonymized JMDC dataset only, informed consent and ethical review\/approval were not required for this study. The permission to access the JMDC database was under the license between Pfizer Japan Inc. and JMDC Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}